Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Phase II study of Femprox in FSAD completed

April 4, 2002

Marketing clearance sought for Aldurazyme in Europe

April 4, 2002

Combination of Androsorb and Estrasorb examined in hormone-deficient women

April 4, 2002

European Commission provides financial support for diabetes project

April 3, 2002

VEGF antagonist attenuates estrogen-mediated increase in uterine mass, endometrial area

April 3, 2002

First thyroid hormone receptor modulator from BMS/Karo Bio collaboration discontinued

April 2, 2002

Novavax presents new results on Estrasorb at Society of Gynecologic Investigation meeting

April 2, 2002

Administration of antarelix associated with acute delay in folliculogenesis, followed by recovery

April 2, 2002

Cellegy commences phase II/III trial of Tostrelle for treatment of FSD

March 28, 2002

Dynepo receives E.U. approval for anemia of renal failure

March 28, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 24, 2026.
Have brain-computer interfaces finally arrived?
BioWorld
More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
K2 nabs two Antengene bispecific TCEs in $2B license, option deal
BioWorld
MPM Bioimpact-spawned K2 Therapeutics Inc. inked a license deal plus option agreement, worth $980.5 million apiece, to gain ex-China rights to two of Antengene...
In the clinic for June 22, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Alkermes, Boehringer, Cambrian, F2G, Intrabio, Lexeo, Memo, Novocure,...